These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32368252)

  • 1. Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic.
    Martí C; Sánchez-Méndez JI
    Ecancermedicalscience; 2020; 14():1027. PubMed ID: 32368252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delays in operative management of early-stage, estrogen receptor-positive breast cancer during the COVID-19 pandemic: A multi-institutional matched historical cohort study.
    Di Lena É; Hopkins B; Wong SM; Meterissian S
    Surgery; 2022 Mar; 171(3):666-672. PubMed ID: 34862071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of early breast cancer during the COVID-19 pandemic in Brazil.
    Cavalcante FP; Novita GG; Millen EC; Zerwes FP; de Oliveira VM; Sousa ALL; Freitas Junior R
    Breast Cancer Res Treat; 2020 Nov; 184(2):637-647. PubMed ID: 32803637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept.
    Iwata H
    Breast Cancer; 2011 Apr; 18(2):92-7. PubMed ID: 21140250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocol for a Systematic Review Assessing Surgery versus Primary Endocrine Therapy in Operable Breast Cancer. Prep for Pandemic.
    Roberts S; Rojas A; Gachabayov M; Castaldi M
    Int J Surg Protoc; 2020; 24():36-38. PubMed ID: 33294752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
    Whitworth P; Beitsch P; Mislowsky A; Pellicane JV; Nash C; Murray M; Lee LA; Dul CL; Rotkis M; Baron P; Stork-Sloots L; de Snoo FA; Beatty J
    Ann Surg Oncol; 2017 Mar; 24(3):669-675. PubMed ID: 27770345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptation of international coronavirus disease 2019 and breast cancer guidelines to local context.
    Valencia GA; Neciosup S; Gómez HL; Benites MDP; Falcón S; Moron D; Veliz K; Maldonado M; Auqui R
    World J Clin Oncol; 2021 Jan; 12(1):31-42. PubMed ID: 33552937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer patients with hormone neoadjuvant bridging therapy due to asymptomatic Corona virus infection. Case report, clinical and histopathologic findings.
    Pellicciaro M; Granai AV; Marchese G; Materazzo M; Cotesta M; Santori F; Giacobbi E; Servadei F; Grelli S; Perretta T; Meucci R; Pistolese CA; Vanni G
    Int J Surg Case Rep; 2020; 76():377-380. PubMed ID: 33052300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative concurrent endocrine therapy with chemotherapy in luminal B-like breast cancer.
    Matsunuma R; Watanabe T; Hozumi Y; Koizumi K; Ito Y; Maruyama S; Ogura H; Goto K; Mori H; Sawai N; Shiiya N
    Breast Cancer; 2020 Sep; 27(5):819-827. PubMed ID: 32144735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
    Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
    Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic.
    Park KU; Gregory M; Bazan J; Lustberg M; Rosenberg S; Blinder V; Sharma P; Pusztai L; Shen C; Partridge A; Thompson A
    Breast Cancer Res Treat; 2021 Jul; 188(1):249-258. PubMed ID: 33651271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in breast cancer management during the Corona Virus Disease 19 pandemic: An international survey of the European Breast Cancer Research Association of Surgical Trialists (EUBREAST).
    Gasparri ML; Gentilini OD; Lueftner D; Kuehn T; Kaidar-Person O; Poortmans P
    Breast; 2020 Aug; 52():110-115. PubMed ID: 32502796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
    Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
    JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of COVID-19 pandemic in a breast unit: Is it possible to avoid delays in surgical treatment?
    Kiziltan G; Tumer BKC; Guler OC; Ozaslan C
    Int J Clin Pract; 2021 Dec; 75(12):e14995. PubMed ID: 34710280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach.
    Sheng JY; Santa-Maria CA; Mangini N; Norman H; Couzi R; Nunes R; Wilkinson M; Visvanathan K; Connolly RM; Roussos Torres ET; Fetting JH; Armstrong DK; Tao JJ; Jacobs L; Wright JL; Thorner ED; Hodgdon C; Horn S; Wolff AC; Stearns V; Smith KL
    JCO Oncol Pract; 2020 Oct; 16(10):665-674. PubMed ID: 32603252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of the SARS-COV-2 pandemic on the quality of breast cancer care in EUSOMA-certified breast centres.
    van Dam P; Tomatis M; Ponti A; Marotti L; Aristei C; Biganzoli L; Cardoso MJ; Cheung KL; Curigliano G; De Vries J; Santini D; Sardanelli F; Rubio IT;
    Eur J Cancer; 2022 Dec; 177():72-79. PubMed ID: 36332437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Model as a Platform for Research in Breast Cancer and Novel Targets under Development in this Field.
    Escrivá-de-Romaní S; Arumí M; Zamora E; Bellet M
    Breast Care (Basel); 2018 Aug; 13(4):251-262. PubMed ID: 30319327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints.
    Yeo B; Dowsett M
    Breast; 2015 Nov; 24 Suppl 2():S78-83. PubMed ID: 26255746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant endocrine therapy in ER-positive breast cancer: evolution, indication, and tailored treatment strategy.
    Jeong H; Kim SB
    Ther Adv Med Oncol; 2023; 15():17588359231200457. PubMed ID: 37786536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.